Takeda adds a $790M discovery deal to an ongoing R&D overhaul
Focusing hard on overhauling R&D, Takeda has moved from reorganizing and downsizing to inking new collaborations with discovery outfits around the world.
Today the global Japanese company, which has been concentrating much of its research power in the Cambridge, MA area, has aligned itself with Crescendo Biologics in Cambridge, UK. Takeda is committing $36 million in near-term cash and a further $754 million in milestones to jump on board the biotech’s Humabody platform, which relies on its unique transgenic mouse model to find compact antibodies that have the potential to make tempting drug programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.